title: [Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment].
abstract: Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome--hyperinsulinemia, arterial hypertension, dyslipidemia and obesity--leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases--antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.
authors.affiliation: Research Centre of Neurology, Moscow, Russia.
authors.forename: M M
authors.initials: MM
authors.lastname: Tanashyan
authors.affiliation: Research Centre of Neurology, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Lagoda
authors.affiliation: Research Centre of Neurology, Moscow, Russia.
authors.forename: K V
authors.initials: KV
authors.lastname: Antonova
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006487:Hemostasis; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications; D006973:Hypertension / Q000150:complications; D024821:Metabolic Syndrome / Q000150:complications*; D009765:Obesity / Q000150:complications
chemical_list: D000975:Antioxidants; D005343:Fibrinolytic Agents